RegeneRx Biopharmaceuticals, Inc. Receives Clinical Study Report for Phase 2 Dry Eye Trial

Published: Jan 05, 2012

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) announced today that it has received the clinical study report for its recently completed Phase 2 clinical trial evaluating RGN-259 for the treatment of dry eye syndrome. The following conclusions were highlighted in the report’s summary:

•“The efficacy of RGN-259 for the topical treatment of the primary signs and symptoms of dry eye was proven with this study by its protective effects to adverse stimuli as well as its enhanced repair at 24-hour recovery after CAE [controlled adverse environment] challenge.”

Back to news